氨基酸调节剂聚天冬酰胺酶与维奈克拉联合治疗复发或难治性急性髓系白血病的1期研究
该1期研究评估了聚天冬酰胺酶(PegC)联合维奈克拉(Ven)治疗成人复发或难治性急性髓系白血病(AML)的安全性和疗效,包括既往接受过Ven的患者。主要终点为方案限制性毒性(RLT)发生率和最大耐受剂量(MTD)。结果显示高胆红素血症为RLT,MTD为Ven 400 mg每日联合PegC 750 IU/m2每两周一次,可评估患者的总完全缓解率为33%。
要点
- 高胆红素血症是VenPegC方案的方案限制性毒性,60%患者发生,20%为≥3级。
- 最大耐受剂量为Ven 400 mg每日联合PegC 750 IU/m2每两周一次。
- 可评估患者总完全缓解率为33%,RUNX1突变患者复合完全缓解率为100%。
核心结论
- VenPegC联合方案在复发或难治性AML患者中确定了最大耐受剂量,并显示出一定疗效。
研究设计与样本
- 1期研究纳入25例接受至少1剂PegC联合Ven的成人复发或难治性AML患者,其中18例可评估疗效。
主要发现
- 25例患者中高胆红素血症发生率为60%,其中20%为≥3级。
- 25例患者中最常见的任何级别治疗相关不良事件包括抗凝血酶III降低(52%)、转氨酶升高(36%-48%)、乏力(28%)和低纤维蛋白原血症(24%)。
- 未观察到血栓栓塞或出血不良事件或临床胰腺炎。
- 18例可评估疗效患者的总完全缓解率为33%。
- RUNX1突变患者的复合完全缓解率为100%。
关键数值与推荐
- 最大耐受剂量为Ven 400 mg每日联合PegC 750 IU/m2每两周一次。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glutamine dependency has been shown to be a metabolic vulnerability in acute myeloid leukemia (AML). Prior studies using several in vivo AML models showed that depletion of plasma glutamine, induced by long-acting crisantaspase (pegcrisantaspase [PegC]) was synergistic with the B-cell lymphoma-2 (BCL-2) inhibitor venetoclax (Ven), resulting in significantly reduced leukemia burden and enhanced survival. Here, we report a phase 1 study of the combination of Ven and PegC (VenPegC) for treating adult patients with relapsed or refractory AML, including patients who had previously received Ven. The primary end points were the incidence of regimen-limiting toxicities (RLTs) and the maximum tolerated dose (MTD). Twenty-five patients received at least 1 PegC dose with Ven, and 18 efficacy-evaluable patients completed at least 1 VenPegC cycle; 12 (67%) had previously received Ven. Hyperbilirubinemia was the RLT and occurred in 60% of patients treated with VenPegC; 20% had grade ≥3 bilirubin elevations. MTD was determined to be Ven 400 mg daily with biweekly PegC 750 IU/m2. The most common treatment-related adverse events of any grade in 25 patients who received VenPegC included antithrombin III decrease (52%), elevated transaminases (36%-48%), fatigue (28%), and hypofibrinogenemia (24%). No thromboembolic or hemorrhagic adverse events or clinical pancreatitis were observed. The overall complete remission rate in efficacy-evaluable patients was 33%. Response correlated with alterations in proteins involved in messenger RNA translation. In patients with RUNX1 mutations, the composite complete remission rate was 100%. This study was registered at www.ClinicalTrials.gov as #NCT04666649.
引用
- Liu Y, Bollino DR, Bah OM, et al. A phase 1 study of the amino acid modulator pegcrisantaspase and venetoclax for relapsed or refractory acute myeloid leukemia. Blood. 2025. PMID: 39437546. doi:10.1182/blood.2024024837
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。